OneThree Biotech Announces $2.5M Seed Funding & Free Toxicity Screening for Small Molecules Treating COVID-19 | Markets Insider
Summary
OneThree Biotech (OTB) is a graduate of Cornell Techs Runway Startup program and uses biology-driven AI to accurately predict new potential therapeutics and to pinpoint the underlying biological mechanisms driving drug efficacy. The company was first started in 2018 by Neel S. Madhukar, Ph.D., a PhRMA Foundations Informatics Fellowship recipient recognized on the Forbes "30 Under 30" list, and Olivier Elemento, Ph.D., Director of the Caryl and Israel Englander Institute for Precision Medicine, Associate Director of the Institute for Computational Biomedicine, and Co-Director of the WorldQuant Initiative for Quantitative Prediction at Weill Cornell Medicine. "OneThrees unique AI-driven approach promises to bring enormous efficiency to clinical trials, enabling the right drugs to get to market quicker than ever. "Were incredibly grateful for the support of our investors and partners as we push forward and show we can use biology-driven AI to redesign the drug discovery process. "The results of the trial highlighted how their technology can improve the outcome of patients diagnosed with rare brain cancer by identifying treatments that shrink these tumors, which has never been seen before.